Introduction

Autoimmune diseases occur when the immune system loses tolerance to self-antigens, driving chronic inflammation and tissue damage. While genetic predisposition contributes significantly, the incomplete concordance among monozygotic twins points to additional regulatory layers. Epigenetic modifications—molecular alterations that change gene expression without altering the DNA sequence—have become central to understanding autoimmune susceptibility. These modifications integrate environmental exposures, lifestyle factors, and stochastic events to shape immune cell function and self-tolerance. Unraveling epigenetic mechanisms not only clarifies disease pathogenesis but also reveals new opportunities for biomarkers and targeted therapies. This review examines the major epigenetic mechanisms, their roles in specific autoimmune diseases, the influence of environmental triggers, and the translational potential for prevention and treatment.

What Are Epigenetic Modifications?

Epigenetic modifications alter chromatin structure and gene accessibility without changing the underlying DNA code. They are dynamic, often reversible, and responsive to both internal and external signals. The three key mechanisms are DNA methylation, histone modifications, and non‑coding RNA regulation. Each contributes to the precise control of gene expression necessary for immune cell development and function.

DNA Methylation

DNA methylation typically involves the addition of a methyl group to the 5′ position of cytosine within CpG dinucleotides, catalyzed by DNA methyltransferases (DNMTs). Hypermethylation of promoter regions generally silences transcription, whereas hypomethylation can activate or overexpress genes. In the immune system, methylation patterns help define cell-type-specific gene expression, regulating cytokines, chemokines, and transcription factors. Aberrant methylation remains one of the most extensively studied epigenetic marks in autoimmunity.

Histone Modifications

Histone proteins (H2A, H2B, H3, H4) form nucleosomes around which DNA is wrapped. Post‑translational modifications of histone tails—including acetylation, methylation, phosphorylation, and ubiquitination—alter chromatin compaction and recruit effector proteins. Histone acetylation, mediated by histone acetyltransferases (HATs) and deacetylases (HDACs), is generally associated with open, transcriptionally active chromatin. Histone methylation can be activating or repressive depending on the residue and degree of methylation. Disrupted histone modification landscapes have been repeatedly linked to dysregulated immune gene expression in autoimmune diseases.

Non‑Coding RNAs

Non‑coding RNAs, including microRNAs (miRNAs) and long non‑coding RNAs (lncRNAs), regulate gene expression post‑transcriptionally or by guiding chromatin-modifying complexes. miRNAs fine‑tune immune responses by targeting mRNAs involved in T‑cell differentiation, B‑cell activation, and inflammatory signaling. Altered miRNA profiles are associated with several autoimmune conditions and are being investigated as diagnostic and therapeutic targets.

The Connection Between Epigenetics and Autoimmune Diseases

Genome‑wide studies have revealed extensive epigenetic dysregulation in patients with autoimmune diseases. These alterations affect immune regulatory genes, leading to loss of self‑tolerance, aberrant cytokine production, and sustained inflammation. Below we examine key autoimmune disorders and their epigenetic hallmarks, highlighting specific genes and pathways.

Systemic Lupus Erythematosus (SLE)

SLE is a prototypic systemic autoimmune disease characterized by autoantibodies against nuclear antigens. Global DNA hypomethylation in CD4+ T cells is a consistent finding, notably in genes encoding immune mediators such as CD11a (ITGAL), CD70 (TNFSF7), and perforin. Hypomethylation of interferon-regulated genes contributes to the type I interferon signature that drives lupus pathology. Histone modifications also play a role: decreased repressive mark H3K9me3 and increased activating mark H3K4me3 at pro-inflammatory loci have been observed. MiR‑146a, a negative regulator of interferon responses, is underexpressed in SLE, further fueling inflammation. These epigenetic changes may be triggered by environmental factors like ultraviolet light, viral infections (e.g., Epstein‑Barr virus), or drugs such as procainamide and hydralazine, which inhibit DNMT activity.

Rheumatoid Arthritis (RA)

Rheumatoid arthritis involves chronic inflammation of synovial joints driven by autoreactive T and B cells. Fibroblast‑like synoviocytes (FLS) in RA exhibit a unique DNA methylome, with widespread hypomethylation at genes linked to cell migration, matrix degradation, and immune activation. For example, hypomethylation of the CXCL12 promoter elevates chemokine expression, attracting inflammatory cells. Histone deacetylase (HDAC) expression is altered in RA synovial tissue, shifting the balance toward pro-inflammatory gene transcription. Several miRNAs (e.g., miR‑155, miR‑146a) are dysregulated in RA and correlate with disease activity. Epigenetic changes in RA are influenced by smoking (which interacts with HLA‑DRB1 shared epitope alleles), infection (e.g., Porphyromonas gingivalis), and mechanical stress on joints.

Multiple Sclerosis (MS)

Multiple sclerosis is a demyelinating autoimmune disease of the central nervous system. CD4+ T cells from MS patients show aberrant DNA methylation in genes controlling T‑cell differentiation, such as FOXP3 in regulatory T cells. Hypomethylation of IL17A and other Th17‑associated genes enhances pathogenic responses. Histone modifications in oligodendrocytes may impair remyelination. Environmental risk factors like vitamin D deficiency, Epstein‑Barr virus infection, and smoking likely exert their effects through epigenetic mechanisms. For instance, vitamin D receptor binding modifies histone acetylation at immune loci, and EBV proteins can recruit DNMTs to alter host methylation.

Type 1 Diabetes (T1D)

T1D results from autoimmune destruction of pancreatic β‑cells. Studies on monozygotic twins discordant for T1D reveal differential DNA methylation in genes involved in immune regulation and β‑cell function, including INS (insulin) and HLA class II loci. Hypomethylation of IFNGR2 enhances interferon‑γ signaling, promoting β‑cell apoptosis. Viral infections (e.g., enteroviruses) may trigger methylation changes that break tolerance. Epigenetic signatures are being explored as early‑stage biomarkers to predict T1D before clinical onset, potentially allowing preventive interventions.

Other Autoimmune Diseases

Systemic sclerosis (scleroderma) features DNA hypomethylation of collagen- and fibrosis-related genes, while inflammatory bowel disease (IBD) shows altered methylation in intestinal epithelial cells and immune cells. Sjögren’s syndrome patients exhibit hypomethylation of interferon-regulated genes in salivary gland tissue. Psoriasis and vitiligo also demonstrate epigenetic dysregulation in skin and immune cells. These examples underscore the common theme of epigenetic dysregulation across autoimmune conditions, though each disease has a distinct methylome and histone modification pattern.

Environmental and Lifestyle Factors That Shape the Epigenome

Epigenetic marks are malleable and respond to a wide range of exposures. Understanding how these factors influence autoimmune risk is central to both prevention and management. The interplay between genetics and environment is often mediated by epigenetic changes.

Infections

Microbial and viral infections can alter host epigenetic landscapes. Epstein‑Barr virus (EBV) encodes proteins such as LMP1 and EBNA2 that recruit host DNMTs and HDACs, modifying methylation and histone marks to promote viral latency and disrupt immune regulation. EBV infection is a strong risk factor for SLE and MS. Similarly, gut microbiota composition influences the host methylome and histone acetylation, affecting intestinal and systemic immune homeostasis. Short-chain fatty acids produced by commensal bacteria, like butyrate, inhibit HDACs and promote regulatory T cell differentiation.

Smoking

Cigarette smoke contains thousands of chemicals that can induce DNA methylation changes. Smoking is associated with global hypomethylation of repetitive elements and site-specific hyper- or hypomethylation at immune-related genes. In RA, smoking interacts with HLA‑DRB1 shared epitope alleles to increase disease risk—a classic gene-environment interaction mediated epigenetically. Quitting smoking can partially reverse some methylation changes, highlighting therapeutic potential. Smoking also affects histone modifications and miRNA expression.

Diet and Nutrition

Dietary components such as folate, vitamin B12, and methionine are substrates for one‑carbon metabolism, directly affecting DNA methylation capacity. Folate deficiency can lead to global hypomethylation, while supplementation may restore methylation patterns. Vitamin D acts as a hormone that influences histone acetylation and methylation at immune loci; vitamin D deficiency has been linked to increased MS and SLE risk. Omega‑3 fatty acids, polyphenols (e.g., curcumin, resveratrol), and other bioactive compounds can modulate histone acetylation and miRNA expression. These nutraceuticals are being studied for their ability to maintain a healthy epigenetic profile and reduce autoimmune risk.

Stress and Hormones

Chronic psychological stress alters the hypothalamic-pituitary-adrenal axis and can induce epigenetic changes in immune cells. Glucocorticoid receptor methylation is increased in individuals with early-life trauma, leading to impaired cortisol signaling and heightened inflammation. Sex hormones (estrogen, testosterone) also influence epigenetic marks, partly explaining the female predominance of many autoimmune diseases. Estrogen can reduce DNMT expression and promote hypomethylation of immune genes, potentially contributing to lupus flares. Testosterone, on the other hand, tends to have protective effects in some autoimmune models.

Physical Activity and Sleep

Regular exercise is associated with beneficial epigenetic modifications, including reduced methylation of anti-inflammatory genes and increased histone acetylation. Sleep deprivation, on the other hand, can alter DNA methylation in immune pathways and elevate inflammatory markers. Circadian rhythm disruption also affects immune cell function via epigenetic mechanisms. Integrating lifestyle modifications that support a healthy epigenome may serve as cost-effective strategies to complement pharmacological interventions.

Epigenetic Biomarkers in Diagnosis and Prognosis

Epigenetic marks have immense potential as biomarkers for early diagnosis, disease stratification, and monitoring treatment response. In SLE, hypomethylation of interferon-regulated genes in blood cells can distinguish patients from healthy controls and correlate with disease activity. In RA, methylation patterns in peripheral blood mononuclear cells can predict radiographic progression and response to methotrexate. For T1D, methylation changes in the INS gene appear years before clinical onset, offering a window for prevention. Epigenetic clocks—based on age-related methylation changes—can also indicate biological aging and inflammation burden in autoimmune patients. However, standardizing assays, accounting for cell-type heterogeneity, and validating across populations remain challenges before clinical implementation.

Implications for Treatment and Prevention

The reversible nature of epigenetic changes positions them as attractive therapeutic targets. Several drug classes are in development or already approved for other indications, and ongoing trials explore their repurposing for autoimmune diseases.

Epigenetic Drugs

DNA methyltransferase inhibitors (DNMTi) such as 5‑azacytidine and decitabine are used in myelodysplastic syndromes and have shown promise in lupus models by reversing T‑cell hypomethylation. However, their global effects raise concerns about off-target toxicity. More selective inhibitors targeting specific DNMT isoforms or delivery via nanoparticles may improve safety. Histone deacetylase inhibitors (HDACi) like vorinostat, romidepsin, and entinostat are approved for certain cancers. In autoimmune settings, they can suppress pro-inflammatory cytokine production and enhance regulatory T‑cell function. For instance, HDACi reduces arthritis severity in RA models by downregulating TNF‑α and IL‑6. Histone methyltransferase inhibitors (e.g., targeting EZH2) and BET bromodomain inhibitors are also being investigated. Notably, JQ1 (a BET inhibitor) attenuates lupus nephritis in mouse models and reduces Th17 responses. Clinical trials of HDACi in RA and SLE are ongoing, with early results showing safety and potential efficacy.

Non‑Coding RNA Therapeutics

MiRNA mimics and antagomirs are entering clinical trials for various diseases, including cancer and fibrosis. In autoimmunity, restoring levels of miR‑146a (a negative regulator of interferon) or blocking miR‑155 (pro-inflammatory) could rebalance immune responses. LncRNAs are also emerging as targets; for example, lncRNA GAS5 modulates glucocorticoid receptor signaling and is dysregulated in SLE. Challenges include delivery, stability, and tissue specificity, but nanocarriers, lipid nanoparticles, and chemical modifications are improving prospects. One phase 2 trial of a miR‑155 inhibitor in lupus is expected to report results soon.

Personalized Medicine and Biomarkers

Epigenetic signatures can stratify patients, predict disease course, and guide treatment choices. Methylation patterns in blood cells may serve as early diagnostic markers and can be used to monitor disease activity. For example, methylation status at the IFN locus could guide the use of type I interferon inhibitors like anifrolumab in SLE. Combining genetic, epigenetic, and environmental data enables a truly personalized approach. Epigenome-wide association studies (EWAS) are identifying new drug targets and biomarkers, which will likely become part of clinical decision-making in the coming decade.

Lifestyle Interventions

Diet, exercise, stress reduction, and smoking cessation can influence the epigenome. Implementing these changes early in high-risk individuals may delay or prevent disease onset. Nutritional supplements with epigenetic effects (e.g., folate, vitamin D, omega‑3s) are being tested in prevention trials. For example, the VITAL trial is testing vitamin D and omega‑3s for autoimmune disease prevention. Environmental modification (e.g., reducing exposure to pollutants, managing infections) may help maintain a stable, healthy epigenetic landscape. Integrating lifestyle counseling into rheumatology practice could enhance conventional therapies.

Epigenetic Editing and Future Directions

Precise manipulation of epigenetic marks at specific genomic loci has become possible with tools like CRISPR‑dCas9 fused with DNMTs, TET enzymes, or HATs/HDACs. These epigenome‑editing systems allow targeted rewriting of methylation and histone marks to correct aberrant states. In proof-of-concept studies, dCas9‑DNMT3A has been used to silence pro-inflammatory genes in immune cells. However, off-target effects, delivery to relevant cell types, and long-term stability need to be addressed. Another emerging area is the use of patient-derived induced pluripotent stem cells (iPSCs) to model autoimmune diseases and screen epigenetic drugs. Single-cell epigenomics is providing unprecedented resolution to identify cell-type-specific changes that are masked in bulk tissue. Longitudinal studies are needed to differentiate causal from correlative epigenetic changes, and to understand how early-life exposures shape lifelong autoimmune risk.

Challenges and Remaining Questions

Despite remarkable progress, several hurdles remain. The heterogeneity of epigenetic changes across cell types and individuals complicates biomarker development. Many studies rely on bulk tissue rather than purified cell populations, masking cell-type-specific effects. Single-cell epigenomics is addressing this, but computational integration with transcriptomics and proteomics is still evolving. Longitudinal studies are needed to differentiate causal from correlative epigenetic changes. Additionally, the dynamic nature of the epigenome requires careful timing of measurements and interventions. Animal models have been invaluable, but species differences in epigenetic regulation require validation in human systems. Ethical considerations around epigenetic editing, especially in germline cells, also need careful debate. Public health efforts to raise awareness about modifiable risk factors could have a population-level impact on autoimmune incidence, but translating epigenetic discoveries into clinical practice requires robust, standardized assays and user-friendly computational tools.

Conclusion

Epigenetic modifications are fundamental to the development and progression of autoimmune diseases. By bridging genetic predisposition and environmental triggers, they explain much of the variability in disease susceptibility and course. DNA methylation, histone modifications, and non‑coding RNAs are all implicated in the dysregulated immune responses seen in SLE, RA, MS, T1D, and beyond. The reversible nature of these modifications offers exciting therapeutic opportunities: epigenetic drugs, miRNA‑based therapies, and lifestyle interventions are already being explored in clinical settings. Continued research into precise mechanisms, improved biomarkers, and safe, targeted epigenome‑editing tools will likely transform the management of autoimmune diseases. For patients, this means hope for more effective treatments and, ultimately, personalized prevention strategies that address the root causes of immune dysregulation.

Further Reading